In his weekly clinical update, Dr. Griffin reviews recent measles outbreaks, prequalification of nOPV2 by the WHO and most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US before discussing COVID-19 deaths linked to SNPs in C-reactive protein, spread of recent viral variants, how early vaccination reduced hospitalization of those infected with XBB.1.5, reviewed quarantine guidelines, how oral antivirals reduce hospitalizations, dissociation of antiviral treatment from infection rebound, and long COVID, deaths due to administration of hydroxychloroquine, muscle abnormalities and extreme fatigue in individuals with long COVID-19 and how the economics of where you live make long COVID-19 more severe.

Click arrow to play
Download TWiV 1078 (51 MB .mp3, 71 min)Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• A national measles campaign (CDC)
• A nation of measles (CDC)
• The measles unvaccinated in NY (CNN)
• Philadelphia’s measles story (Phila gov) 4:18
• January’s measles outbreak (CNN)
• Prequalify of nOPV2 by WHO (GPEI) 7:21
• Did you prequalify for the novel poliovirus vaccine (CIDRAP)
• Respiratory  disease surveillance (CDC) 10:19
• RSV surveillance  (CDC)
• RSV national trend(CDC)
• Influenza/flu surveillance (CDC) 10:45
• Influenza/flu map (CDC)
• COVID-19  hospital admissions (CDC)
• COVID-19 national trend (CDC) 11:56
• COVID-19 wastewater testing (biobot)
• Death rate and C-reactive protein SNPs and COVID-19 (Scientific Reports)
• Variant tracker (CDC) 14:29
• Tracking variant hospitalizations (CDC)
• Early vaccination against XBB.1.5 hospitalization (Eurosurveillance) 22:30
• Vaccination dashboard (Netherlands) 26:04
• Quarantine/isolation guidelines (CDC)
• Antiviral gap among the non-hospitalized high risk adults (CID) 27:32
• Oral antivirals prevent hospitalization (medRxiv) 28:58
• Rebound with and without oral antivirals (MMWR) 31:35
• Randomized rebound trials (MMWR) 32:18
• Know your COVID-19 tools (ESMED) 32:39
• The PASC-paxlovid relationship (JAMA) 33:20
• Molnupiravir safety and efficacy (JMV) 33:35
• Convalescent plasma remmendation for immunocompromised (IDSociety) 33:40
• Fluvoxamine for COVID-19 outpatient (RMV) 33:47
• Death by hydroxychloroquine (Biomedicine & Pharmacotherapy) 37:01
• Steroids, dexamethasone at the right time (OFID) 41:31
• Anticoagulation guidelines (hematology.org) 42:20
• Doxycycline for prevention of progression of COVID-19 (PLoS One) 42:44
• Muscle abnormalities in long COVID (Nat Comm) 48:01
• Discovery of persistent fatigue in long COVID-19 (Amsterdam Univ Med Crr) 57:08
• IMPACC study post-acute sequelae results (Nat Comm) 58:48
• Double course of long COVID in low income countries (Nat) 1:00:20
• Contribute to our MicrobeTV fundraiser at PWB 1:02:01
• Letters read on TWiV 1078 1:02:35
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update, Dr. Griffin highlights global circulation of Mpox virus, reviews the most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US, and discusses the clinical outcome of hospitalized children under 5 years infected with SARS-CoV-2, the perinatal and neonatal outcomes including adverse effects of SARS-CoV-2 infection and virus transmission in Italy between early 2020 and 2022, the guidelines to improve home ventilation, the safety and efficacy of the oral anti-viral molnupiravir and the use of convalescent plasma as a long term treatment as well as treatment specifically for the immune compromised, the ineffectiveness of antibiotics for treating COVID-19, the association of olfactory dysfunction and the administration of corticosteroids and the safety of the RSV vaccines licensed last year.

Click arrow to play

Download TWiV 1075 (20 MB .mp3, 28 min)

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Articles and graphs cited in TWIV CU 1076
• Global mpox circulation (WHO) 1:33
• Mpox in the Americas and Europe (CIDRAP) 1:33
• Respiratory  disease surveillance (CDC)
• RSV surveillance  (CDC)
• RSV national trend (CDC)
• Influenza/flu surveillance  (CDC)
• Influenza/flu map (CDC)
• COVID-19  hospital admissions (CDC)
• COVID-19 national trend (CDC)
• COVID-19 wastewater testing (biobot) 4:16
• Vaccine-Eligible Children Under-5 Years (PIDJ) 4:32
• Pre-school cohort vaccination rate (CIDRAP)
• Perinatal transmission and neonatal outcomes (IJID) 6:39
• Adverse maternal and neonatal effect (dgalerts)
• Ventilation home improvements (CDC) 8:35
• Quarantine/isolation guidelines (CDC)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma remmendation for immunocompromised (IDSociety)
• Corticosteroids in SARS-CoV-2
• Anticoagulation guidelines (hematology.org) 9:43
• Corticosteroids induced olfactory dysfunction (PLoS One) 10:14
• Convalescent Plasma Therapy: Long Term Implications (OFID) 13:43
• Preventing RSV infection by vaccination (MMWR)
• Antivirals and chronic kidney disease (CID)
• Early administraton of molnupiravir versus ritonavir-boosted nirmatrelvir (Lancet Infectious Diseases)
• Contribute to our MicrobeTV fundraiser at PWB 15:58
• Letters read on TWiV 1076 16:18
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update, Dr. Griffin discusses the outcomes of SARS-CoV-2, influenza and respiratory syncytial virus infection in pediatric communities under the age of 18 years, the treatment of infants with the human monoclonal anti-respiratory syncytial virus antibody to prevent hospitalizations, most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US, how the SARS-CoV-2/COVID-19 pandemic affected school attendance and child healthcare, how exposure length influenced transmission of SARS-CoV-2, how the durability of the anti-SARS-CoV-2 antibody response to protect against virus re-infection, if administration of oral antiviral therapy affected viral rebound in either the unvaccinated or vaccinated populations, as well as a reminder of the ineffectiveness of antibiotics for treating COVID-19 and the effect of vaccination on post-COVID conditions in children between 5-17 years old.

Click arrow to play

Download TWiV 1074 (33 MB .mp3, 46 min)

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Pediatric outcomes SARS-CoV-2, flu, RSV (JAMA Peds.)2:13
• SARS-CoV-2 vs Flu  (Wired) 2:27
• Anti-RSV antibody treatment for infants (NEJM) 6:05
• Respiratory  disease surveillance (CDC)
• RSV surveillance  (CDC) 8:19
• RSV national trend (CDC)
• Influenza/flu surveillance  (CDC) 8:57
• COVID-19  hospital admissions (CDC) 9:52
• COVID-19 national trend (CDC) 9:51
• COVID-19 wastewater testing (biobot) 10:17
• COVID-19 school attendance (JPEIDS) 11:28
• COVID-19 pandemic effects children health care (JPEIDS) 13:30
• Digitally measuring transmission (Nat) 15:31
• Antibody titers and re-infection (CMI) 18:39
• Oral antiviral and SARS-CoV-2 rebound (MMWR) 22:57
• Rebound after antiviral controlled trial (MMWR) 24:58
• Vaccination and antiviral therapy (OFID) 26:45
• Antivirals and hospitalization (JMV) 27:53
• Antivirals molnupiravir (JMV) 31:13
• Convalescent plasma and the immunocompromised guidelines (IDSOciety) 31:18
• Steroid and the cytokine storm (OFID) 31:56
• Anticoagulation guidelines (hematology.org) 31:35
• Unnecessary antibiotics (NEJM) 32:18
• Vaccination and long COVID (OFID) 32:55
• RSV vaccination (MMWR)
• Antivirals and chronic kidney disease (CID)
• Early administraton of molnupiravir versus ritonavir-boosted nirmatrelvir (Lancet)
• Contribute to our MicrobeTV fundraiser at PWB 36:24
• Letters read on TWiV 1074 37:03
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update Dr. Griffin discusses the annual economic burden of respiratory syncytial virus in adults in the US, recombinant or standard-dose influenza vaccine in adults under 65 years of age, maternal vaccine effectiveness against influenza-associated hospitalizations and emergency department visits in iInfants, influenza positive tests reported to CDC by US clinical laboratories, update on COVID-19, risk of severe maternal morbidity associated with SARS-CoV-2 infection during pregnancy, COVID-19 rapid antigen tests with self-collected vs health care worker–collected nasal and throat swab specimens, optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation, long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study, and risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.

Click arrow to play

Download TWiV 1072 (28 MB .mp3, 39 min)

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• RSV economic burden, US (J Inf Dis) 3:10
• Recombinant or standard dose influenza vaccine (NEJM) 6:50
• Maternal vaccine effectiveness against influenza in Infants (JAMA Ped) 11:18
• Weekly influenza surveillance report (MMWR) 14:06
• COVID data tracker (hospital admissions, national trend) 13:19
• Risk of severe maternal morbidity associated with SARS-CoV-2 infection (J Inf Dis) 14:43
• COVID-19 rapid antigen tests with nasal and throat swab specimens (JAMA Net Open) 17:01
• Optimal timing of nirmatrelvir/ritonavir (Nat Comm) 18:40
• Long-term outcomes following hospital admission for COVID-19 vs influenza (Lancet) 23:39
• Risk of arrhythmias following COVID-19 case series (European Heart Journal Open) 26:50
• Contribute to our MicrobeTV fundraiser at PWB 28:35
• Letters read on TWiV 1072 29:03
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update, Dr. Griffin discusses monkeypox and chickenpox co-infection in southern Nigeria, vaccine effectiveness against influenza A, SARS-CoV-2 neutralizing antibody titers in maternal blood, umbilical cord blood, and breast milk, COVID-19 rapid antigen tests with self-collected vs health care worker–collected nasal and throat swab specimens, four methods for monitoring SARS-CoV-2 and Influenza A virus activity in schools, efficacy and safety of Baricitinib for the treatment of hospitalized adults with COVID-19, a synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong, consistent absence of cerebrospinal fluid biomarker abnormalities in patients with neurocognitive post-COVID complications, and risk of new-onset long COVID following reinfection with SARS-CoV-2.

Click arrow to play

Download TWiV 1070 (29 MB .mp3, 40 min)

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Monkeypox and chickenpox co-infection in southern Nigeria (JID) 5:27
• Vaccine effectiveness against influenza A (CID) 8:36
• SARS-CoV-2 neutralizing antibody titers in maternal blood, umbilical cord blood, and breast milk (JOP) 12:48
• COVID-19 rapid antigen tests with self-collected vs health care worker–collected nasal and throat swab specimens (JAMA) 15:04
• Four methods for monitoring SARS-CoV-2 and influenza A virus activity in schools (JAMA) 22:16
• Efficacy and safety of Baricitinib for the treatment of hospitalized adults with COVID-19 (EJMR) 24:14
• A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (The Lancet) 25:30
• Consistent absence of cerebrospinal fluid biomarker abnormalities in patients with neurocognitive post-COVID complications (JID) 29:39
• Risk of new-onset long COVID following reinfection with SARS-CoV-2 (OFID) 30:57
• Contribute to our MicrobeTV fundraiser at PWB 32:42
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv